Brain pathways with addiction and recovery symbols

Can a New Drug End Opioid Addiction? VK4-116 Shows Promise

Rhea Morgan in Health & Wellness December 2025 • 5 min read.

"A novel dopamine D3 receptor antagonist, VK4-116, could revolutionize opioid addiction treatment without sacrificing pain relief, offering hope for a safer, more effective path to recovery."

The opioid crisis in the United States continues to be a major public health concern, driven by the misuse and abuse of prescription painkillers like oxycodone. While these drugs are effective for managing pain, their addictive potential has led to widespread devastation, highlighting the urgent need for new and effective treatments.

Recent research offers a glimmer of hope in the fight against opioid addiction. Scientists have been exploring the potential of a novel compound called VK4-116, a highly selective dopamine D3 receptor (D3R) antagonist. This innovative approach targets the brain's reward system to curb addictive behaviors without compromising pain relief.

This article dives into the groundbreaking study investigating VK4-116's effects on oxycodone addiction in rats, examining its potential to reduce drug-seeking behavior, enhance pain management, and ease withdrawal symptoms. We'll explore how VK4-116 works, its potential benefits, and what this means for the future of opioid addiction treatment.

VK4-116: A New Approach to Opioid Addiction Treatment

Brain pathways with addiction and recovery symbols

The study, published in Neuropsychopharmacology, investigated the effects of VK4-116 on various aspects of oxycodone addiction in laboratory rats. The results are compelling, suggesting VK4-116 could be a game-changer in how we approach opioid addiction treatment.

Here's a breakdown of the key findings:

Reduced Oxycodone Self-Administration: VK4-116 dose-dependently inhibited the acquisition and maintenance of oxycodone self-administration. Rats treated with VK4-116 were less likely to seek and consume oxycodone.
Lowered Breakpoint for Oxycodone: The compound lowered the "breakpoint" for oxycodone self-administration under a progressive-ratio schedule of reinforcement. This indicates that the rats were less motivated to work for the drug.
Inhibited Drug-Seeking Behavior: VK4-116 reduced oxycodone extinction responding and reinstatement of oxycodone-seeking behavior, suggesting it can prevent relapse.
Enhanced Pain Relief: Remarkably, VK4-116 enhanced the antinociceptive effects of oxycodone. This means that the rats experienced greater pain relief from the same dose of oxycodone.
Reduced Withdrawal Symptoms: VK4-116 reduced naloxone-precipitated conditioned place aversion in rats chronically treated with oxycodone, indicating a lessening of withdrawal symptoms.
No Impact on Natural Rewards: Importantly, VK4-116 had little effect on oral sucrose self-administration, suggesting it selectively targets drug-related reward pathways rather than blunting all pleasurable experiences.

These findings indicate that VK4-116's mechanism of action centers on the dopamine D3 receptors, playing a critical role in opioid reward. This makes VK4-116 a strong candidate for further development as a treatment for opioid addiction, potentially reducing the severity of withdrawal and preventing relapse without diminishing the analgesic properties of opioids.

The Future of VK4-116 and Opioid Addiction Treatment

The research on VK4-116 offers a promising step forward in the fight against opioid addiction. By selectively targeting dopamine D3 receptors, VK4-116 has the potential to reduce drug-seeking behavior, enhance pain relief, and minimize withdrawal symptoms – all crucial components of successful addiction treatment.

While these findings are encouraging, it's important to remember that this study was conducted on laboratory rats. Further research, including clinical trials in humans, is necessary to confirm VK4-116's safety and effectiveness. The researchers also highlight that VK4-116 has a stable metabolic profile across species, suggesting a high translational potential, increasing the likelihood of success in human trials.

If VK4-116 proves to be effective in humans, it could revolutionize the way we treat opioid addiction, offering a safer, more effective path to recovery for millions of people struggling with this devastating disease. The research team is already conducting further evaluations of VK4-116's therapeutic utility in nonhuman primates, paving the way for future clinical applications.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1038/s41386-018-0284-5, Alternate LINK

Title: Dopamine D3R Antagonist Vk4-116 Attenuates Oxycodone Self-Administration And Reinstatement Without Compromising Its Antinociceptive Effects

Subject: Psychiatry and Mental health

Journal: Neuropsychopharmacology

Publisher: Springer Science and Business Media LLC

Authors: Zhi-Bing You, Guo-Hua Bi, Ewa Galaj, Vivek Kumar, Jianjing Cao, Alexandra Gadiano, Rana Rais, Barbara S. Slusher, Eliot L. Gardner, Zheng-Xiong Xi, Amy Hauck Newman

Published: 2018-11-27

Everything You Need To Know

What is VK4-116, and how does it work to combat opioid addiction?

VK4-116 is a selective dopamine D3 receptor antagonist. It works by targeting the dopamine D3 receptors in the brain, which play a crucial role in the reward pathways associated with opioid addiction. By blocking these receptors, VK4-116 aims to reduce drug-seeking behavior and cravings without diminishing the pain-relieving effects of opioids.

What specific benefits were observed in the study regarding VK4-116's effect on oxycodone addiction in rats?

The study on VK4-116 showed several promising results in rats. These included a reduction in oxycodone self-administration, a lowered breakpoint for oxycodone indicating reduced motivation to seek the drug, inhibition of drug-seeking behavior suggesting it can prevent relapse, enhanced pain relief from oxycodone, and reduced withdrawal symptoms. Importantly, VK4-116 did not significantly impact the natural reward system.

Why is the potential of VK4-116 to enhance pain relief while reducing opioid addiction considered a significant advancement?

VK4-116's ability to enhance pain relief while reducing addiction is significant because many opioid addiction treatments can compromise pain management, leading to relapse. The selective targeting of dopamine D3 receptors by VK4-116 offers a potential path to managing both addiction and pain effectively, which is a major challenge in treating patients dependent on opioids.

How does VK4-116 affect the natural reward system, and why is this important for addiction treatment?

The study found that VK4-116 had little impact on oral sucrose self-administration in rats. This is crucial because it suggests that VK4-116 selectively targets the drug-related reward pathways associated with opioid addiction, rather than blunting all pleasurable experiences. This selectivity could reduce the risk of anhedonia, a common side effect where individuals lose interest in all pleasurable activities, which can hinder addiction recovery.

What are the next steps in researching VK4-116, and what further studies are needed before it can be considered a viable treatment for opioid addiction in humans?

While the research on VK4-116 is promising, further research is needed to confirm its safety and efficacy in humans. Clinical trials are essential to determine the appropriate dosage, potential side effects, and long-term effects of VK4-116. It's also important to investigate its effectiveness in diverse populations and in combination with other addiction treatment approaches, such as behavioral therapy and counseling, to fully understand its potential as a comprehensive treatment for opioid addiction.